[HTML][HTML] Myocardial postischemic injury is reduced by polyADPribose polymerase-1 gene disruption

AA Pieper, T Walles, G Wei, EE Clements, A Verma… - Molecular …, 2000 - Springer
AA Pieper, T Walles, G Wei, EE Clements, A Verma, SH Snyder, JL Zweier
Molecular medicine, 2000Springer
Background PolyADPribose polymerase (PARP) is activated by DNA strand breaks to
catalyze the addition of ADPribose groups to nuclear proteins, especially PARP-1.
Excessive polyADPribosylation leads to cell death through depletion of NAD+ and ATP.
Materials and Methods In vivo PARP activation in heart tissue slices was assayed through
conversion of [33 P] NAD+ into polyADPribose (PAR) following ischemia-reperfusion (I/R)
and also monitored by immunohistochemical staining for PAR. Cardiac contractility, nitric …
Background
PolyADPribose polymerase (PARP) is activated by DNA strand breaks to catalyze the addition of ADPribose groups to nuclear proteins, especially PARP-1. Excessive polyADPribosylation leads to cell death through depletion of NAD+ and ATP.
Materials and Methods
In vivo PARP activation in heart tissue slices was assayed through conversion of [33P]NAD+ into polyADPribose (PAR) following ischemia-reperfusion (I/R) and also monitored by immunohistochemical staining for PAR. Cardiac contractility, nitric oxide (NO), reactive oxygen species (ROS), NAD+ and ATP levels were examined in wild type (WT) and in PARP-1 gene-deleted (PARP-1−/−) isolated, perfused mouse hearts. Myocardial infarct size was assessed following coronary artery occlusion in rats treated with PARP inhibitors.
Results
Ischemia-reperfusion (I/R) augmented formation of nitric oxide, oxygen free radicals and PARP activity. I/R induced decreases in cardiac contractility and NAD+ levels were attenuated in PARP-1−/− mouse hearts. PARP inhibitors reduced myocardial infarct size in rats. Residual polyADPribosylation in PARP-1−/− hearts may reflect alternative forms of PARP.
Conclusions
PolyADPribosylation from PARP-1 and other sources of enzymatic PAR synthesis is associated with cardiac damage following myocardial ischemia. PARP inhibitors may have therapeutic utility in myocardial disease.
Springer